Glycans as targets for therapeutic antitumor antibodies

Future Oncology

Volumn 8, Issue 8, 2012, Pages 943-960

  Rabu, Catherine ^a   McIntosh, Richard ^a   Jurasova, Zuzana ^a   Durrant, Lindy ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

ganglioside; GD2; GD3; glycan; glycosphingolipid; GM2; Lewis antigens; N glycolylneuraminic acid; therapeutic monoclonal antibody

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; BCG VACCINE; CALICHEAMICIN; CANCER ANTIBODY; CYCLOPHOSPHAMIDE; DOXORUBICIN; ECROMEXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FC RECEPTOR; FLUOROURACIL; GANGLIOSIDE GD2; GANGLIOSIDE GD3; GANGLIOSIDE GM2; GLYCAN; HISTONE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 2; MITUMOMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY F77; MONOCLONAL ANTIBODY R24; MONOCLONAL ANTIBODY RAV12; MULTIDRUG RESISTANCE PROTEIN 1; PSEUDOMONAS EXOTOXIN; RACOTUMOMAB; SIALYLTETRAOSYLCERAMIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTIBODY RESPONSE; APOPTOSIS; BLADDER CANCER; BLOOD GROUP LEWIS SYSTEM; BREAST CANCER; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RISK; CARCINOGENICITY; CELL METABOLISM; CELL SURFACE; CELLS; COMPLEMENTARITY DETERMINING REGION; DEACETYLATION; DEPHOSPHORYLATION; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; EVENT FREE SURVIVAL; GENE LOCUS; GLYCOSYLATION; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IN VITRO STUDY; LEWIS CARCINOMA; LIVER TOXICITY; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MELANOMA CELL; METASTASIS; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR GROWTH; UPREGULATION; URTICARIA;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; NEOPLASMS; POLYSACCHARIDES;

EID: 84865218061     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.88     Document Type: Review

References (150)

1. Cummings RD. The repertoire of glycan determinants in the human glycome. Mol. Biosyst. 5(10), 1087-1104 (2009).
2. Chester MA. IUPAC-IUB Joint Commission on Biochemical Nomenclature (JCBN). Nomenclature of glycolipids-recommendations 1997. Eur. J. Biochem. 257(2), 293-298 (1998).
3. Schnaar R, Suzuki A, Stanley P. Structure and biosynthesis of glycosphingolipids. In: Essentials of Glycobiology (2nd Edition). Varki A, Cummings RD, Esko JD et al. (Eds). Cold Spring Harbor Laboratory Press, NY, USA (2009).
4. Stanley P, Schachter H, Taniguchi N. Structure and biosynthesis of N-glycans. In: Essentials of Glycobiology (2nd Edition). Varki A, Cummings RD, Esko JD et al. (Eds). Cold Spring Harbor Laboratory Press, NY, USA (2009).
5. Hakomori S. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc. Natl Acad. Sci. USA 99(16), 10231-10233 (2002).
6. Cheever MA, Allison JP, Ferris AS et al. The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research. Clin. Cancer Res. 15(17), 5323-5337 (2009).
7. Hakomori S. Tumor-associated glycolipid antigens, their metabolism and organization. Chem. Phys. Lipids 42(1-3), 209-233 (1986).
8. Izawa M, Kumamoto K, Mitsuoka C et al. Expression of sialyl 6-sulfo Lewis X is inversely correlated with conventional sialyl Lewis X expression in human colorectal cancer. Cancer Res. 60(5), 1410-1416 (2000).
9. Kannagi R. Molecular mechanism for cancer-associated induction of sialyl Lewis X and sialyl Lewis A expression-The Warburg effect revisited. Glycoconj. J. 20(5), 353-364 (2004).
10. Fuster MM, Esko JD. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat. Rev. Cancer 5(7), 526-542 (2005).
11. Hakomori S-I. The glycosynapse. Proc. Natl Acad. Sci. USA 99(1), 225-232 (2002).
12. Song WX, Vacca MF, Welti R, Rintoul DA. Effects of gangliosides GM3 and De-N-acetyl GM3 on epidermal growth factor receptor kinase activity and cell growth. J. Biol. Chem. 266(16), 10174-10181 (1991).
13. Steelant WF, Kawakami Y, Ito A et al. Monosialyl-Gb5 organized with cSrc and FAK in GEM of human breast carcinoma MCF-7 cells defines their invasive properties. FEBS Lett. 531(1), 93-98 (2002).
14. Van Slambrouck S, Steelant WF. Clustering of monosialyl-Gb5 initiates downstream signalling events leading to invasion of MCF-7 breast cancer cells. Biochem. J. 401(3), 689-699 (2007).
15. Mitsuzuka K, Handa K, Satoh M, Arai Y, Hakomori S. A specific microdomain ("glycosynapse 3") controls phenotypic conversion and reversion of bladder cancer cells through GM3-mediated interaction of a3b1 integrin with CD9. J. Biol. Chem. 280(42), 35545-35553 (2005).
16. Zhang Q, Furukawa K, Chen HH, Sakakibara T, Urano T. Metastatic potential of mouse Lewis lung cancer cells is regulated via ganglioside GM1 by modulating the matrix metalloprotease-9 localization in lipid rafts. J. Biol. Chem. 281(26), 18145-18155 (2006).
17. Nakano J, Raj BK, Asagami C, Lloyd KO. Human melanoma cell lines deficient in GD3 ganglioside expression exhibit altered growth and tumorigenic characteristics. J. Invest. Dermatol. 107(4), 543-548 (1996).
18. Hamamura K, Furukawa K, Hayashi T et al. Ganglioside GD3 promotes cell growth and invasion through p130Cas and paxillin in malignant melanoma cells. Proc. Natl Acad. Sci. USA 102(31), 11041-11046 (2005).
19. Nakamori S, Kameyama M, Imaoka S et al. Increased expression of sialyl Lewisx antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study. Cancer Res. 53(15), 3632-3637 (1993).
20. Portela SV, Martin CV, Romay LM, Cuevas E, Martin EG, Briera AF. sLea and sLex expression in colorectal cancer: implications for tumourigenesis and disease prognosis. Histol. Histopathol. 26(10), 1305-1316 (2011).
21. Iwamori M, Iwamori Y, Kubushiro K, Ishiwata I, Kiguchi K. Characteristic expression of Lewis-antigenic glycolipids in human ovarian carcinoma-derived cells with anticancer drug-resistance. J. Biochem. 141(3), 309-317 (2007).
22. Liu YY, Gupta V, Patwardhan GA et al. Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and b-catenin signaling. Mol. Cancer 9, 145 (2010).
23. Birkle S, Zeng G, Gao L, Yu RK, Aubry J. Role of tumor-associated gangliosides in cancer progression. Biochimie 85(3-4), 455-463 (2003).
24. Takahashi T, Johnson TD, Nishinaka Y, Morton DL, Irie RF. IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients. J. Invest. Dermatol. 112(2), 205-209 (1999).
25. Irie RF, Ollila DW, O'Day S, Morton DL. Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma. Cancer Immunol. Immunother. 53(2), 110-117 (2004).
26. Zeng Y, Fest S, Kunert R et al. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Mol. Immunol. 42(11), 1311-1319 (2005).
27. Imai M, Landen C, Ohta R, Cheung NK, Tomlinson S. Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. Cancer Res. 65(22), 10562-10568 (2005).
28. Desjarlais JR, Lazar GA, Zhukovsky EA, Chu SY. Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discov. Today 12(21-22), 898-910 (2007).
29. Sato F, Ito A, Ishida T et al. A complement-dependent cytotoxicity-enhancing anti-CD20 antibody mediating potent antitumor activity in the humanized NOD/Shi-scid, IL-2Rg (null) mouse lymphoma model. Cancer Immunol. Immunother. 59(12), 1791-1800 (2010).
30. Burris HA 3rd, Rosen LS, Rocha-Lima CM et al. Phase 1 experience with an anti-glycotope monoclonal antibody, RAV12, in recurrent adenocarcinoma. Clin. Cancer Res. 16(5), 1673-1681 (2010).
31. Lonberg N. Fully human antibodies from transgenic mouse and phage display platforms. Curr. Opin Immunol. 20(4), 450-459 (2008).
32. Shields RL, Lai J, Keck R et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcg RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277(30), 26733-26740 (2002).
33. Mizushima T, Yagi H, Takemoto E et al. Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans. Genes Cells 16(11), 1071-1080 (2011).
34. Schuster M, Jost W, Mudde GC et al. In vivo glyco-engineered antibody with improved lytic potential produced by an innovative non-mammalian expression system. Biotechnol. J. 2(6), 700-708 (2007).
35. Natsume A, In M, Takamura H et al. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res. 68(10), 3863-3872 (2008).
36. Hernandez AM, Rodriguez N, Gonzalez JE et al. Anti-NeuGcGM3 antibodies, actively elicited by idiotypic vaccination in nonsmall cell lung cancer patients, induce tumor cell death by an oncosis-like mechanism. J. Immunol. 186(6), 3735-3744 (2011).
37. Loo D, Pryer N, Young P et al. The glycotope-specific RAV12 monoclonal antibody induces oncosis in vitro and has antitumor activity against gastrointestinal adenocarcinoma tumor xenografts in vivo. Mol. Cancer Ther. 6(3), 856-865 (2007).
38. Zhang G, Zhang H, Wang Q et al. Suppression of human prostate tumor growth by a unique prostate-specific monoclonal antibody F77 targeting a glycolipid marker. Proc. Natl Acad. Sci. USA 107(2), 732-737 (2009).
39. Aixinjueluo W, Furukawa K, Zhang Q et al. Mechanisms for the apoptosis of small cell lung cancer cells induced by anti-GD2 monoclonal antibodies: roles of anoikis. J. Biol. Chem. 280(33), 29828-29836 (2005).
40. Zhang S, Cordon-Cardo C, Zhang HS et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int. J. Cancer 73(1), 42-49 (1997).
41. Yoshida S, Fukumoto S, Kawaguchi H, Sato S, Ueda R, Furukawa K. Ganglioside G(D2) in small cell lung cancer cell lines: enhancement of cell proliferation and mediation of apoptosis. Cancer Res. 61(10), 4244-4252 (2001).
42. Irie RF, Morton DL. Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Proc. Natl Acad. Sci. USA 83(22), 8694-8698 (1986).
43. Cheung NK, Kushner BH, Yeh SD, Larson SM. 3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a Phase II study. Int. J. Oncol. 12(6), 1299-1306 (1998).
44. Grant SC, Kostakoglu L, Kris MG et al. Targeting of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: a pilot trial. Eur. J. Nucl. Med. 23(2), 145-149 (1996).
45. Kushner BH, Kramer K, Modak S, Cheung NK. Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a Phase I study. J. Clin. Oncol. 29(9), 1168-1174 (2011).
46. Cheung NK, Cheung IY, Canete A et al. Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival. Cancer Res. 54(8), 2228-2233 (1994).
47. Cheung NK, Guo HF, Heller G, Cheung IY. Induction of Ab3 and Ab3́ antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma. Clin. Cancer Res. 6(7), 2653-2660 (2000).
48. Cheung NK, Sowers R, Vickers AJ, Cheung IY, Kushner BH, Gorlick R. FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. J. Clin. Oncol. 24(18), 2885-2890 (2006).
49. Murray JL, Cunningham JE, Brewer H et al. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J. Clin. Oncol. 12(1), 184-193 (1994).
50. Saleh MN, Khazaeli MB, Wheeler RH et al. Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer Res. 52(16), 4342-4347 (1992).
51. Frost JD, Hank JA, Reaman GH et al. A Phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Cancer 80(2), 317-333 (1997).
52. Hank JA, Robinson RR, Surfus J et al. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res. 50(17), 5234-5239 (1990).
53. Ozkaynak MF, Sondel PM, Krailo MD et al. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study. J. Clin. Oncol. 18(24), 4077-4085 (2000).
54. Gilman AL, Ozkaynak MF, Matthay KK et al. Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group. J. Clin. Oncol. 27(1), 85-91 (2009).
55. Yu AL, Gilman AL, Ozkaynak MF et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N. Engl. J. Med. 363(14), 1324-1334 (2010).
56. Simon T, Hero B, Faldum A et al. Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J. Clin. Oncol. 22(17), 3549-3557 (2004).
57. Simon T, Hero B, Faldum A et al. Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. BMC Cancer 11, 21 (2011).
58. Yu AL, Uttenreuther-Fischer MM, Huang CS et al. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J. Clin. Oncol. 16(6), 2169-2180 (1998).
59. Albertini MR, Hank JA, Schiller JH et al. Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients. Clin. Cancer Res. 3(8), 1277-1288 (1997).
60. Hank JA, Gan J, Ryu H et al. Immunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma. Clin. Cancer Res. 15(18), 5923-5930 (2009).
61. Shusterman S, London WB, Gillies SD et al. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) Phase II study. J. Clin. Oncol. 28(33), 4969-4975 (2010).
62. Buhtoiarov IN, Neal ZC, Gan J et al. Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting. J. Leukoc. Biol. 89(4), 625-638 (2011).
63. Pule MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol. Ther. 12(5), 933-941 (2005).
64. Lo AS, Ma Q, Liu DL, Junghans RP. Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors. Clin. Cancer Res. 16(10), 2769-2780 (2010).
65. Yvon E, Del Vecchio M, Savoldo B et al. Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. Clin. Cancer Res. 15(18), 5852-5860 (2009).
66. Louis CU, Savoldo B, Dotti G et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118(23), 6050-6056 (2011).
67. Ye JN, Cheung NK. A novel O-acetylated ganglioside detected by anti-GD2 monoclonal antibodies. Int. J. Cancer 50(2), 197-201 (1992).
68. Alvarez-Rueda N, Desselle A, Cochonneau D et al. A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity. PLoS ONE 6(9), e25220 (2011).
69. Bardor M, Nguyen DH, Diaz S, Varki A. Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells. J. Biol. Chem. 280(6), 4228-4237 (2005).
70. Varki A. Colloquium paper: uniquely human evolution of sialic acid genetics and biology. Proc. Natl Acad. Sci. USA 107(Suppl. 2), S8939-S8946 (2010).
71. Malykh YN, Schauer R, Shaw L. N-glycolylneuraminic acid in human tumours. Biochimie 83(7), 623-634 (2001).
72. Nguyen DH, Tangvoranuntakul P, Varki A. Effects of natural human antibodies against a nonhuman sialic acid that metabolically incorporates into activated and malignant immune cells. J. Immunol. 175(1), 228-236 (2005).
73. Carr A, Mullet A, Mazorra Z et al. A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors. Hybridoma 19(3), 241-247 (2000).
74. Fernandez-Marrero Y, Roque-Navarro L, Hernandez T et al. A cytotoxic humanized anti-ganglioside antibody produced in a murine cell line defective of N-glycolylated-glycoconjugates. Immunobiology 216(12), 1239-1247 (2011).
75. Carr A, Mesa C, del Carmen Arango M, Vazquez AM, Fernandez LE. In vivo and in vitro anti-tumor effect of 14F7 monoclonal antibody. Hybrid Hybridom. 21(6), 463-468 (2002).
76. Oliva JP, Valdes Z, Casaco A et al. Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with (99m)Tc. Breast Cancer Res. Treat. 96(2), 115-121 (2006).
77. Roque-Navarro L, Chakrabandhu K, de Leon J et al. Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity. Mol. Cancer Ther. 7(7), 2033-2041 (2008).
78. Vazquez AM, Gabri MR, Hernandez AM et al. Antitumor properties of an anti-idiotypic monoclonal antibody in relation to N-glycolyl-containing gangliosides. Oncol. Rep. 7(4), 751-756 (2000).
79. Fuentes D, Avellanet J, Garcia A et al. Combined therapeutic effect of a monoclonal anti-idiotype tumor vaccine against NeuGc-containing gangliosides with chemotherapy in a breast carcinoma model. Breast Cancer Res. Treat. 120(2), 379-389 (2010).
80. Diaz Y, Gonzalez A, Lopez A, Perez R, Vazquez AM, Montero E. Anti-ganglioside anti-idiotypic monoclonal antibody-based cancer vaccine induces apoptosis and antiangiogenic effect in a metastatic lung carcinoma. Cancer Immunol. Immunother. 58(7), 1117-1128 (2009).
81. Alfonso M, Diaz A, Hernandez AM et al. An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J. Immunol. 168(5), 2523-2529 (2002).
82. Diaz A, Alfonso M, Alonso R et al. Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides. Clin. Immunol. 107(2), 80-89 (2003).
83. Hernandez AM, Toledo D, Martinez D et al. Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody. J. Immunol. 181(9), 6625-6634 (2008).
84. Vazquez AM. Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing-gangliosides. Pre-clinical and clinical data. Presented at: PIVAC. Copenhagen, Denmark, 11 October 2011.
85. Reaman GH, Taylor BJ, Merritt WD. Anti-GD3 monoclonal antibody analysis of childhood T-cell acute lymphoblastic leukemia: detection of a target antigen for antibody-mediated cytolysis. Cancer Res. 50(1), 202-205 (1990).
86. Merritt WD, Der-Minassian V, Reaman GH. Increased GD3 ganglioside in plasma of children with T-cell acute lymphoblastic leukemia. Leukemia 8(5), 816-822 (1994).
87. Bajorin DF, Chapman PB, Wong G et al. Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma. Cancer Res. 50(23), 7490-7495 (1990).
88. Minasian LM, Szatrowski TP, Rosenblum M et al. Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor-a and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanoma. Blood 83(1), 56-64 (1994).
89. Minasian LM, Yao TJ, Steffens TA et al. A Phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma. Cancer 75(9), 2251-2257 (1995).
90. Alpaugh RK, von Mehren M, Palazzo I et al. Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/a-interferon. Med. Oncol. 15(3), 191-198 (1998).
91. Bukowski RM, Murthy SA, Finke J et al. Phase I trial of cisplatin, WR-2721, and the murine monoclonal antibody R24 in patients with metastatic melanoma: clinical and biologic effects. J. Immunother. Emphasis Tumor Immunol. 15(4), 273-282 (1994).
92. Nasi ML, Meyers M, Livingston PO, Houghton AN, Chapman PB. Anti-melanoma effects of R24, a monoclonal antibody against GD3 ganglioside. Melanoma Res. 7(Suppl. 2), S155-S162 (1997).
93. Kirkwood JM, Mascari RA, Edington HD et al. Analysis of therapeutic and immunologic effects of R(24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma. Cancer 88(12), 2693-2702 (2000).
94. Bajorin DF, Chapman PB, Wong GY et al. Treatment with high dose mouse monoclonal (anti-GD3) antibody R24 in patients with metastatic melanoma. Melanoma Res. 2(5-6), 355-362 (1992).
95. Scott AM, Liu Z, Murone C et al. Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma. Cancer Immun. 5, 3 (2005).
96. Forero A, Shah J, Carlisle R et al. A Phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanoma. Cancer Biother. Radiopharm. 21(6), 561-568 (2006).
97. Nakamura K, Tanaka Y, Shitara K, Hanai N. Construction of humanized anti-ganglioside monoclonal antibodies with potent immune effector functions. Cancer Immunol. Immunother. 50(5), 275-284 (2001).
98. McCaffery M, Yao TJ, Williams L, Livingston PO, Houghton AN, Chapman PB. Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant. Clin. Cancer Res. 2(4), 679-686 (1996).
99. Chapman PB, Williams L, Salibi N, Hwu WJ, Krown SE, Livingston PO. A Phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside. Vaccine 22(21-22), 2904-2909 (2004).
100. Grant SC, Kris MG, Houghton AN, Chapman PB. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guérin. Clin. Cancer Res. 5(6), 1319-1323 (1999).
101. Giaccone G, Debruyne C, Felip E et al. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J. Clin. Oncol. 23(28), 6854-6864 (2005).
102. Ramos AS, Parise CB, Travassos LR, Han SW, de Campos-Lima PO, de Moraes JZ. The idiotype (Id) cascade in mice elicited the production of anti-R24 Id and anti-anti-Id monoclonal antibodies with antitumor and protective activity against human melanoma. Cancer Sci. 102(1), 64-70 (2011).
103. Yamada T, Bando H, Takeuchi S et al. Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasis produced by GM2-expressing small-cell lung cancer cells. Cancer Sci. 102(12), 2157-2163 (2011).
104. Manimala JC, Roach TA, Li Z, Gildersleeve JC. High-throughput carbohydrate microarray profiling of 27 antibodies demonstrates widespread specificity problems. Glycobiology 17(8), 17C-23C (2007).
105. Hellstrom I, Garrigues HJ, Garrigues U, Hellstrom KE. Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Le(y)-related cell surface antigens. Cancer Res. 50(7), 2183-2190 (1990).
106. Posey JA, Khazaeli MB, Bookman MA et al. A Phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors. Clin. Cancer Res. 8(10), 3092-3099 (2002).
107. Pai LH, Wittes R, Setser A, Willingham MC, Pastan I. Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nat. Med. 2(3), 350-353 (1996).
108. Kuan CT, Pai LH, Pastan I. Immunotoxins containing Pseudomonas exotoxin that target LeY damage human endothelial cells in an antibody-specific mode: relevance to vascular leak syndrome. Clin. Cancer Res. 1(12), 1589-1594 (1995).
109. Wahl AF, Donaldson KL, Mixan BJ, Trail PA, Siegall CB. Selective tumor sensitization to taxanes with the mAb-drug conjugate cBR96-doxorubicin. Int. J. Cancer 93(4), 590-600 (2001).
110. Ross HJ, Hart LL, Swanson PM et al. A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma. Lung Cancer 54(1), 69-77 (2006).
111. Tolcher AW, Sugarman S, Gelmon KA et al. Randomized Phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J. Clin. Oncol. 17(2), 478-484 (1999).
112. Ajani JA, Kelsen DP, Haller D, Hargraves K, Healey D. A multi-institutional Phase II study of BMS-182248-01 (BR96-doxorubicin conjugate) administered every 21 days in patients with advanced gastric adenocarcinoma. Cancer J. 6(2), 78-81 (2000).
113. Scott AM, Tebbutt N, Lee FT et al. A Phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen. Clin. Cancer Res. 13(11), 3286-3292 (2007).
114. Herbertson RA, Tebbutt NC, Lee FT et al. Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers. Clin. Cancer Res. 15(21), 6709-6715 (2009).
115. Westwood JA, Murray WK, Trivett M et al. The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum. J. Immunother. 32(3), 292-301 (2009).
116. Durrant LG, Harding SJ, Green NH, Buckberry LD, Parsons T. A new anticancer glycolipid monoclonal antibody, SC104, which directly induces tumor cell apoptosis. Cancer Res. 66(11), 5901-5909 (2006).
117. Mordoh J, Silva C, Albarellos M, Bravo AI, Kairiyama C. Phase I clinical trial in cancer patients of a new monoclonal antibody FC-2.15 reacting with tumor proliferating cells. J. Immunother. Emphasis Tumor Immunol. 17(3), 151-160 (1995).
118. Capurro M, Ballare C, Bover L, Portela P, Mordoh J. Differential lytic and agglutinating activity of the anti-Lewis(x) monoclonal antibody FC-2.15 on human polymorphonuclear neutrophils and MCF-7 breast tumor cells. In vitro and ex vivo studies. Cancer Immunol. Immunother. 48(2-3), 100-108 (1999).
119. Elola MT, Capurro MI, Barrio MM et al. Lewis x antigen mediates adhesion of human breast carcinoma cells to activated endothelium. Possible involvement of the endothelial scavenger receptor C-type lectin. Breast Cancer Res. Treat. 101(2), 161-174 (2007).
120. Jorgensen T, Berner A, Kaalhus O, Tveter KJ, Danielsen HE, Bryne M. Up-regulation of the oligosaccharide sialyl LewisX: a new prognostic parameter in metastatic prostate cancer. Cancer Res. 55(9), 1817-1819 (1995).
121. Nakayama T, Watanabe M, Katsumata T, Teramoto T, Kitajima M. Expression of sialyl Lewis(a) as a new prognostic factor for patients with advanced colorectal carcinoma. Cancer 75(8), 2051-2056 (1995).
122. Sawada R, Sun SM, Wu X et al. Human monoclonal antibodies to sialyl-Lewis (CA19.9) with potent CDC, ADCC, and antitumor activity. Clin. Cancer Res. 17(5), 1024-1032 (2011).
123. Dippold WG, Lloyd KO, Li LT, Ikeda H, Oettgen HF, Old LJ. Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies. Proc. Natl Acad. Sci. USA 77(10), 6114-6118 (1980).
124. Ohta S, Honda A, Tokutake Y, Yoshida H, Hanai N. Antitumor effects of a novel monoclonal antibody with high binding affinity to ganglioside GD3. Cancer Immunol. Immunother. 36(4), 260-266 (1993).
125. Vos Q, Lees A, Wu ZQ, Snapper CM, Mond JJ. B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol. Rev. 176, 154-170 (2000).
126. Balazs M, Martin F, Zhou T, Kearney J. Blood dendritic cells interact with splenic marginal zone B cells to initiate T-independent immune responses. Immunity 17(3), 341-352 (2002).
127. Masso O, Alino SF, Lejarreta M, Blasco F, Piulats J. Specific serological response by active immunization with GD3-bearing liposomes. J. Pharmacol. Exp. Ther. 278(3), 1114-1120 (1996).
128. Watarai S, Kiura K, Shigeto R, Shibayama T, Kimura I, Yasuda T. Establishment of monoclonal antibodies specific for ganglioside GM1: detection of ganglioside GM1 in small cell lung carcinoma cell lines and tissues. J. Biochem. 116(5), 948-954 (1994).
129. Livingston PO, Calves MJ, Natoli EJ Jr. Approaches to augmenting the immunogenicity of the ganglioside GM2 in mice: purified GM2 is superior to whole cells. J. Immunol. 138(5), 1524-1529 (1987).
130. Ilyas AA, Chen ZW. Lewis rats immunized with GM1 ganglioside do not develop peripheral neuropathy. J. Neuroimmunol. 188(1-2), 34-38 (2007).
131. Kondo Y, Tokuda N, Furukawa K et al. Efficient generation of useful monoclonal antibodies reactive with globotriaosylceramide using knockout mice lacking Gb3/CD77 synthase. Glycoconj. J. 28(6), 371-384 (2011).
132. Bowes T, Wagner ER, Boffey J et al. Tolerance to self gangliosides is the major factor restricting the antibody response to lipopolysaccharide core oligosaccharides in Campylobacter jejuni strains associated with Guillain-Barré syndrome. Infect. Immun. 70(9), 5008-5018 (2002).
133. Ariga T, Suetake K, Nakane M et al. Glycosphingolipid antigens in neural tumor cell lines and anti-glycosphingolipid antibodies in sera of patients with neural tumors. Neurosignals 16(2-3), 226-234 (2008).
134. Lunn MP, Johnson LA, Fromholt SE et al. High-affinity anti-ganglioside IgG antibodies raised in complex ganglioside knockout mice: reexamination of GD1a immunolocalization. J. Neurochem. 75(1), 404-412 (2000).
135. Katagiri YU, Nakajima H, Sato B et al. The detergent-insoluble microdomains, rafts, can be used as an effective immunogen. Glycoconj. J. 25(6), 495-501 (2008).
136. Hoon DS, Wang Y, Sze L et al. Molecular cloning of a human monoclonal antibody reactive to ganglioside GM3 antigen on human cancers. Cancer Res. 53(21), 5244-5250 (1993).
137. van Kuppevelt TH, Dennissen MA, van Venrooij WJ, Hoet RM, Veerkamp JH. Generation and application of type-specific anti-heparan sulfate antibodies using phage display technology. Further evidence for heparan sulfate heterogeneity in the kidney. J. Biol. Chem. 273(21), 12960-12966 (1998).
138. Yuasa N, Zhang W, Goto T et al. Production of anti-carbohydrate antibodies by phage display technologies: potential impairment of cell growth as a result of endogenous expression. J. Biol. Chem. 285(40), 30587-30597 (2010).
139. Mao S, Gao C, Lo CH, Wirsching P, Wong CH, Janda KD. Phage-display library selection of high-affinity human single-chain antibodies to tumor-associated carbohydrate antigens sialyl Lewisx and Lewisx. Proc. Natl Acad. Sci. USA 96(12), 6953-6958 (1999).
140. Uttenreuther-Fischer MM, Kruger JA, Fischer P. Molecular characterization of the anti-idiotypic immune response of a relapse-free neuroblastoma patient following antibody therapy: a possible vaccine against tumors of neuroectodermal origin? J. Immunol. 176(12), 7775-7786 (2006).
141. Heimburg-Molinaro J, Lum M, Vijay G, Jain M, Almogren A, Rittenhouse-Olson K. Cancer vaccines and carbohydrate epitopes. Vaccine 29(48), 8802-8826 (2011).
142. Mujoo K, Cheresh DA, Yang HM, Reisfeld RA. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res. 47(4), 1098-1104 (1987).
143. Mujoo K, Kipps TJ, Yang HM et al. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Cancer Res. 49(11), 2857-2861 (1989).
144. Mueller BM, Romerdahl CA, Gillies SD, Reisfeld RA. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J. Immunol. 144(4), 1382-1386 (1990).
145. Saleh MN, Stapleton JD, Khazaeli MB, LoBuglio AF. Generation of a human anti-idiotypic antibody that mimics the GD2 antigen. J. Immunol. 151(6), 3390-3398 (1993).
146. Sen G, Chakraborty M, Foon KA, Reisfeld RA, Bhattacharya-Chatterjee MB. Induction of IgG antibodies by an anti-idiotype antibody mimicking disialoganglioside GD2. J. Immunother. 21(1), 75-83 (1998).
147. Foon KA, Lutzky J, Baral RN et al. Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J. Clin. Oncol. 18(2), 376-384 (2000).
148. Neal ZC, Yang JC, Rakhmilevich AL et al. Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy. Clin. Cancer Res. 10(14), 4839-4847 (2004).
149. Kristeleit H. IGN-311. Igeneon. Curr. Opin. Investig. Drugs 6(12), 1272-1279 (2005).
150. Roscoe DM, Pai LH, Pastan I. Identification of epitopes on a mutant form of Pseudomonas exotoxin using serum from humans treated with Pseudomonas exotoxin containing immunotoxins. Eur. J. Immunol. 27(6), 1459-1468 (1997).